Type d'article
Etat
Reliure
Particularités
Pays
Evaluation du vendeur
Edité par LAP LAMBERT Academic Publishing, 2012
ISBN 10 : 3659126551ISBN 13 : 9783659126550
Vendeur : Lucky's Textbooks, Dallas, TX, Etats-Unis
Livre
Etat : New.
Edité par LAP LAMBERT Academic Publishing, 2012
ISBN 10 : 3659126551ISBN 13 : 9783659126550
Vendeur : PBShop.store US, Wood Dale, IL, Etats-Unis
Livre impression à la demande
PAP. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Edité par LAP Lambert Academic Publishing, 2012
ISBN 10 : 3659126551ISBN 13 : 9783659126550
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Livre impression à la demande
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - New drug discovery and development is a complex, flexible and cost-effective but systematic process that follows a sequence of clinical steps, rules and regulations governed by the experienced regulatory authorities in each country. The rules laid down by the experienced authorities consistently have need of the code of ethics by which every individual involved in clinical research has to stand. Besides these ethical principles, a clinical trial involves multidisciplinary functions which require concepts and approaches, using modern research tools and techniques. In this book, the authors discuss some of key functions in clinical trial management as drug development process, clinical trials design, good clinical practices, roles and responsibilities of clinical trial personnel, regulatory processes/issues and the processes involved in performing excellent monitoring functions for the successful clinical study. This book also facilitates the understanding of the importance of ethics in clinical studies and the evolution of various guidelines, rules and regulations for the management of a clinical trials.
Edité par LAP LAMBERT Academic Publishing, 2012
ISBN 10 : 3659126551ISBN 13 : 9783659126550
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
Livre impression à la demande
PAP. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Edité par LAP LAMBERT Academic Publishing, 2012
ISBN 10 : 3659126551ISBN 13 : 9783659126550
Vendeur : ALLBOOKS1, Salisbury Plain, SA, Australie
Livre
Edité par LAP LAMBERT Academic Publishing, 2012
ISBN 10 : 3659126551ISBN 13 : 9783659126550
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Livre
Paperback. Etat : Like New. Like New. book.
Edité par Springer Netherlands, 2010
ISBN 10 : 9048155843ISBN 13 : 9789048155842
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Livre
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene variants that contribute to various multifactorial diseases and genes that exist in certain infectious agents but not humans. As a consequence, this will allow us to define the most appropriate levels for drug intervention. It can be expected that the number of potential drug targets will increase, possibly by a factor of 10 or more. Nevertheless, sequencing the human genome or, for that matter, the genome of other species will only be the starting point for the understanding of their biological function. Structural genomics is a likely follow-up, combined with new techniques to validate the therapeutic relevance of such newly discovered targets. Accordingly, it can be expected that in the near future we will witness a substantial increase in novel putative targets for drugs. To address these new targets effectively, we require new approaches and innovative tools. At present, two alternative, yet complementary, techniques are employed: experimental high-throughput screening (HTS) of large compound libraries, increasingly provided by combinatorial chemistry, and computational methods for virtual screening and de novo design. As kind of status report on the maturity of virtual screening as a technique in drug design, the first workshop on new approaches in drug design and discovery was held in March 1999, at Schloß Rauischholzhausen, near Marburg in Germany. More than 80 scientists gathered and discussed their experience with the different techniques. The speakers were invited to summarize their contributions together with their impressions on the present applicability of their approach. Several of the speakers followed this request which is summarized in this publication.
Edité par Springer Netherlands, 2000
ISBN 10 : 0792366336ISBN 13 : 9780792366331
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Livre
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - In the next couple of years the human genome will be fully sequenced. This will provide us with the sequence and overall function of all human genes as well as the complete genome for many micro-organisms. Subsequently it is hoped, by means of powerful bioinformatic tools, to determine the gene variants that contribute to various multifactorial diseases and genes that exist in certain infectious agents but not humans. As a consequence, this will allow us to define the most appropriate levels for drug intervention. It can be expected that the number of potential drug targets will increase, possibly by a factor of 10 or more. Nevertheless, sequencing the human genome or, for that matter, the genome of other species will only be the starting point for the understanding of their biological function. Structural genomics is a likely follow-up, combined with new techniques to validate the therapeutic relevance of such newly discovered targets. Accordingly, it can be expected that in the near future we will witness a substantial increase in novel putative targets for drugs. To address these new targets effectively, we require new approaches and innovative tools. At present, two alternative, yet complementary, techniques are employed: experimental high-throughput screening (HTS) of large compound libraries, increasingly provided by combinatorial chemistry, and computational methods for virtual screening and de novo design. As kind of status report on the maturity of virtual screening as a technique in drug design, the first workshop on new approaches in drug design and discovery was held in March 1999, at Schloß Rauischholzhausen, near Marburg in Germany. More than 80 scientists gathered and discussed their experience with the different techniques. The speakers were invited to summarize their contributions together with their impressions on the present applicability of their approach. Several of the speakers followed this request which is summarized in this publication.
Edité par Kluwer Academic Pub, 2000
ISBN 10 : 0792366336ISBN 13 : 9780792366331
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Livre
Hardcover. Etat : Brand New. 295 pages. 9.75x6.75x0.75 inches. In Stock.
Edité par Springer International Publishing, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : moluna, Greven, Allemagne
Livre impression à la demande
Gebunden. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. In depth insights into drug discovery and early drug development Latest technologies of target discovery and lead generation   New approaches to transfer drug candidates to clinical development  Dr. Ulrich Nielsch, Ba.
Edité par Springer International Publishing, 2018
ISBN 10 : 3319804553ISBN 13 : 9783319804552
Vendeur : moluna, Greven, Allemagne
Livre impression à la demande
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. In depth insights into drug discovery and early drug development Latest technologies of target discovery and lead generation   New approaches to transfer drug candidates to clinical development  Dr. Ulrich Nielsch, Ba.
Edité par Springer International Publishing Apr 2016, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Livre impression à la demande
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery processstarting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase. 352 pp. Englisch.
Edité par Springer International Publishing Apr 2018, 2018
ISBN 10 : 3319804553ISBN 13 : 9783319804552
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Livre impression à la demande
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase. 352 pp. Englisch.
Edité par Springer, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : GF Books, Inc., Hawthorne, CA, Etats-Unis
Livre
Etat : Fine. Book is in Used-LikeNew condition. Pages and cover are clean and intact. Used items may not include supplementary materials such as CDs or access codes. May show signs of minor shelf wear. 1.41.
Edité par Springer, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : Books Unplugged, Amherst, NY, Etats-Unis
Livre
Etat : New. Buy with confidence! Book is in new, never-used condition 1.41.
Edité par Springer, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : Book Deals, Tucson, AZ, Etats-Unis
Livre
Etat : New. New! This book is in the same immaculate condition as when it was published 1.41.
Edité par Springer International Publishing, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : AHA-BUCH, Einbeck, Allemagne
Livre
Gebundene Ausgabe. Etat : Neu. Neu neuware, auf lager - This volume gives an overview ofstate of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase. 352 pp. Englisch.
Edité par Springer International Publishing, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Livre
Gebundene Ausgabe. Etat : Neu. Neu neuware, auf lager - This volume gives an overview ofstate of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
Edité par Royal Society of Chemistry, 2012
ISBN 10 : 1849734143ISBN 13 : 9781849734141
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Livre
Hardcover. Etat : Like New. Like New. book.
Edité par Springer International Publishing, 2018
ISBN 10 : 3319804553ISBN 13 : 9783319804552
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Livre
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.
Edité par Royal Society of Chemistry, 2012
ISBN 10 : 1849734143ISBN 13 : 9781849734141
Vendeur : booksXpress, Bayonne, NJ, Etats-Unis
Livre
Hardcover. Etat : new.
Edité par Royal Society of Chemistry, 2012
ISBN 10 : 1849734143ISBN 13 : 9781849734141
Vendeur : ALLBOOKS1, Salisbury Plain, SA, Australie
Livre
Edité par Springer, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Livre
Hardcover. Etat : Like New. Like New. book.
Edité par Springer 2016-05-10, 2016
ISBN 10 : 3319289128ISBN 13 : 9783319289120
Vendeur : Chiron Media, Wallingford, Royaume-Uni
Livre
Hardcover. Etat : New.